Navigation Links
Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea
Date:4/10/2008

lop an early clinical stage product, NP-500, for the treatment of insulin resistant diseases of Type II diabetes and metabolic syndrome (Syndrome X; pre-diabetic syndrome). Napo also has a plant library of approximately 2,300 medicinal plants from tropical regions, and Napo has entered two screening relationship associated with this collection. Currently, products are based on the chemical and biological diversity derived from plants with medicinal properties, but future products may be in-licensed from other sources.

Napo has partnerships with Glenmark Pharmaceuticals Limited of India and AsiaPharm Group Ltd. of China. For more information please visit http://www.napopharma.com.

About Glenmark Pharmaceuticals Limited

Glenmark is a leader in India in the discovery of new molecules and is focused in the areas of inflammation [Asthma/COPD, etc.] and metabolic disorders [Diabetes, Obesity, etc.]. The Company is in the process of creating marketing front-ends for the launch of its proprietary products in the future. Glenmark's speciality business alone is guided to generate $306 million (US) in Net Sales in fiscal year 2008 and $352 million (US) in fiscal year 2009. Glenmark's first Asthma/COPD molecule, Oglemilast [GRC 3886], was licensed out to Forest Laboratories and Teijin Pharma Limited for the North American and Japanese markets, respectively, in two landmark deals. Oglemilast is presently undergoing Phase II clinical trials in the US. GRC 6211, undergoing Phase 2 clinical trials in Europe, has been outlicensed to Eli Lilly & company. Visit http://www.glenmarkpharma.com for further details.

About Crofelemer

Crofelemer, a proprietary patented agent, is extracted from Croton lechleri, a medicinal plant which can be sustainably harvested from several countries in South America. Crofelemer is in various stages of clinical d
'/>"/>

SOURCE Napo Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Antipodean Pharmaceuticals Announces Completion of Phase 2 Study of Lead Compound MitoQ(R)
2. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007
3. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
4. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722
5. Favrille Announces Data Cutoff for Phase 3 Registration Trial of Specifid; Data Analysis and Unblinding Expected in June
6. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
7. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
8. Parion Sciences Announces Phase I Clinical Results for Novel Dry Mouth Treatment
9. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
10. Medarex Announces Ipilimumab Program Continues to Move Forward
11. EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha-7 Nicotinic Agonist, EVP-6124, in Patients with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Nov. 26, 2014  Perrigo Company plc ("Perrigo") (NYSE: ... of "Quality Affordable Healthcare Products®," today announced the closing ... the sale of 6,809,210 ordinary shares at a public ... exercise of the option to purchase up to an ... and Barclays Capital Inc., as representatives of the several ...
(Date:11/26/2014)... Nov. 26, 2014 Lexicon Pharmaceuticals, Inc. ... completion of previously announced concurrent financing transactions resulting ... and estimated offering expenses, Lexicon anticipates net proceeds ... transactions consisted of: , a public ... to a registration statement that has been declared ...
(Date:11/26/2014)... , Nov. 26, 2014  Over 100 million ... those suffer from this pain daily. Chronic and acute ... pain management is born to fulfill the need for ... types of pain. On October 28th, a ... Cumberland, Maryland community.  This new ...
Breaking Medicine Technology:Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 2Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 3Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 4Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3New Pain Management Center Opens in Cumberland, Md. 2
... 2010 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ... LLY ) today announced results from a retrospective study ... incidence of events related to cardiovascular disease (CVD) and ... to initiators of other commonly used diabetes medications. These ...
... Reportlinker.com announces that a new market research report ... Global Agricultural Biotechnology Industry ... worldwide markets for Agricultural Biotechnology in US$ Million ... Corn, Cotton, & Others (Includes Canola, Wheat, Rice, ...
Cached Medicine Technology:Study Highlights Incidence of Cardiovascular Disease-Related Events and All-Cause Hospitalizations Associated with BYETTA® Compared to Insulin, Thiazolidinediones, Sulfonylureas, Metformin and Januvia® 2Study Highlights Incidence of Cardiovascular Disease-Related Events and All-Cause Hospitalizations Associated with BYETTA® Compared to Insulin, Thiazolidinediones, Sulfonylureas, Metformin and Januvia® 3Study Highlights Incidence of Cardiovascular Disease-Related Events and All-Cause Hospitalizations Associated with BYETTA® Compared to Insulin, Thiazolidinediones, Sulfonylureas, Metformin and Januvia® 4Study Highlights Incidence of Cardiovascular Disease-Related Events and All-Cause Hospitalizations Associated with BYETTA® Compared to Insulin, Thiazolidinediones, Sulfonylureas, Metformin and Januvia® 5Study Highlights Incidence of Cardiovascular Disease-Related Events and All-Cause Hospitalizations Associated with BYETTA® Compared to Insulin, Thiazolidinediones, Sulfonylureas, Metformin and Januvia® 6Study Highlights Incidence of Cardiovascular Disease-Related Events and All-Cause Hospitalizations Associated with BYETTA® Compared to Insulin, Thiazolidinediones, Sulfonylureas, Metformin and Januvia® 7Reportlinker Adds Global Agricultural Biotechnology Industry 2Reportlinker Adds Global Agricultural Biotechnology Industry 3Reportlinker Adds Global Agricultural Biotechnology Industry 4Reportlinker Adds Global Agricultural Biotechnology Industry 5Reportlinker Adds Global Agricultural Biotechnology Industry 6Reportlinker Adds Global Agricultural Biotechnology Industry 7Reportlinker Adds Global Agricultural Biotechnology Industry 8Reportlinker Adds Global Agricultural Biotechnology Industry 9Reportlinker Adds Global Agricultural Biotechnology Industry 10Reportlinker Adds Global Agricultural Biotechnology Industry 11Reportlinker Adds Global Agricultural Biotechnology Industry 12Reportlinker Adds Global Agricultural Biotechnology Industry 13Reportlinker Adds Global Agricultural Biotechnology Industry 14Reportlinker Adds Global Agricultural Biotechnology Industry 15Reportlinker Adds Global Agricultural Biotechnology Industry 16Reportlinker Adds Global Agricultural Biotechnology Industry 17Reportlinker Adds Global Agricultural Biotechnology Industry 18Reportlinker Adds Global Agricultural Biotechnology Industry 19Reportlinker Adds Global Agricultural Biotechnology Industry 20Reportlinker Adds Global Agricultural Biotechnology Industry 21Reportlinker Adds Global Agricultural Biotechnology Industry 22Reportlinker Adds Global Agricultural Biotechnology Industry 23Reportlinker Adds Global Agricultural Biotechnology Industry 24
(Date:11/27/2014)... 2014 Blood-borne pathogens raise the risk ... and procedures in place to counter this. However, it ... things tainted with menstrual blood are taken as seriously. ... more sanitary way to handle tampons and menstrual pads ... Sonora, Calif. , He then created a prototype of ...
(Date:11/27/2014)... Nov. 26, 2014 (HealthDay News) -- Most babies and ... cold, the U.S. Food and Drug Administration says. ... given to children younger than 2 because they could ... warned. American adults average about three colds a ... get a cold, parents might want to give them ...
(Date:11/27/2014)... November 27, 2014 Jeffrey Carlini ... in the Charlotte area providing audits, reviews, compilations, ... to businesses of varying size across numerous industries. ... to meet all of their accounting and tax ... the QuickBooks ProAdvisor Program. When asking Mr. Carlini ...
(Date:11/27/2014)... DC (PRWEB) November 27, 2014 “Wekho” was ... features the latest and coolest mobile applications on the iOS, ... and host of NewsWatch, conducted the app review ... locations instead of people. , An interesting new way to ... iOS and Android devices. It’s called Wekho and it’s ...
(Date:11/27/2014)... 2014 HealthPostures, a leading ... , has announced that it has entered into ... The partnership will put HealthPostures' products into central ... In addition to having its products sold through ... HealthPostures' products with the business decision makers in ...
Breaking Medicine News(10 mins):Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:Jeffrey Carlini becomes Intuit Proadvisor and receives QuickBooks certification 2Health News:A New Geolocation Mobile Application and was Featured on NewsWatch Television on October 30, 2014 2Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2
... A Cochrane Systematic Review has concluded,Spraying salty water (saline) ... pain and congestion that accompany long-term infections of ... of people experience persistent infection of the nasal passages ... recommend spraying saline into the nose to relieve symptoms, ...
... (FDA) has approved the first artificial cervical (neck) disc for ... the most common causes of neck and arm pain. ... manufactured by Medtronic Sofamor Danek of Memphis. ,The ... degenerative disc disease now will have another surgical option for ...
... found that the chance of successfully quitting can be ... their stay, and then have at least one month ... in to hospital provides an opportunity to stop smoking. ... has to stop temporarily while in hospital. People who ...
... a dose of 20 mg per day can help people ... help prevent the weight gain that so often accompanies attempts ... was not shown to be effective. ,Smoking tobacco ... the endocannabinoid system, part of the hormonal control mechanism in ...
... that a chemical compound found in turmeric may help ... memory . ,Researchers isolated the compound 'bisdemethoxycurcumin' ... system cells that defend the body against infections and ... infuse this compound into patients and treat the incurable ...
... More than a year after President Bush unveiled a plan ... still has limited capacity to detect a disease outbreak ... has also decided that it will not close the borders ... Says Dr. Rajeev Venkayya, special assistant to the president for ...
Cached Medicine News:Health News:FDA Approves First Artificial Cervical Disc 2Health News:Hospital Provides an Oppurtunity to Quit Smoking 2Health News:20 Mg Rimonabant Per Day may Help to Quit Smoking 2Health News:Americas Preparations For Flu Outbreak Still Incomplete 2
Surgical drill bits, twist drills, HSS. Available in various sizes....
... When viewed through the enclosed ... provide a standard screening devise for ... tested. With normal stereo perception, the ... page in 3D. The test includes ...
... a versatile new test providing the broadest ... book. The Multi-Target Stereo test can be ... binocularity, stereopsis, visual attention, form and depth ... version includes a pair of high quality ...
... Stereotest consists of three test plates(6mm, 3mm, and ... a range of 600 - 15 seconds. No ... only be detected if stereopsis is present. Test ... of the patient learning the correct answer. Large ...
Medicine Products: